Sun Pharma has announced it will present 14 abstracts at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27-31 in Denver, Colorado. 

 

The presentations underscore the company’s deep expertise in dermatology and immunology and highlight its ongoing commitment to developing safe, effective treatments for patients with psoriasis, alopecia areata, and acne.

 

“The data we are presenting at AAD underscore our commitment to advancing dermatology and immunology through meaningful science – spanning not only clinical efficacy and safety, but also how these therapies perform over time and in real-world practice,” said Ahmad Naim, Senior Vice President and North American Chief Medical Officer, Sun Pharma. 

 

“Behind every data point is a person, and our responsibility is to continue investment in science that translates into clinically meaningful outcomes for people living with these chronic conditions.”

 

The company’s podium and poster presentations will cover a broad spectrum of conditions:

 

1. ILUMYA (tildrakizumab-asmn): A Phase 3b study in moderate-to-severe psoriasis affecting the nails shows sustained efficacy and safety over 52 weeks. Real-world evidence confirms that ILUMYA delivers comprehensive disease control across diverse populations worldwide. The therapy is approved for moderate-to-severe plaque psoriasis in the US, Australia, Japan, and Europe (as ILUMETRI).

 

2. LEQSELVI (deuruxolitinib): Pooled results from the pivotal THRIVE-AA1 and THRIVE-AA2 trials in severe alopecia areata revealed significant scalp hair regrowth as early as Week 8, with ongoing improvements over time. A landmark survey of patients and clinicians highlighted gaps in understanding disease burden and treatment goals, emphasizing the need for improved communication and alignment for patient-centered care.

 

3. WINLEVI (clascoterone cream 1%): An open-label, 52-week study showed significant reduction in facial sebum production and acne severity, confirming its targeted action on the androgen-sebum pathway. Pilot combination therapies suggest WINLEVI may enhance multimodal acne treatment approaches.

 

These presentations reflect Sun Pharma’s commitment to translating cutting-edge science into meaningful outcomes for patients living with chronic dermatologic conditions.